RightFit
RecruitingNot applicable

Anti-inflammatory Activities of Vitamin C Supplementation on the Gut Barrier Function in Adults With Obesity

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years to 50 Years
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Time periods mentioned: 2 weeks
  • Procedures mentioned: Blood draws, Pills

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "Participants will complete two study periods, each lasting two weeks, with a two-week break in between."
  • "There are minimal risks, such as discomfort from blood draws or temporary stomach upset from a sugar drink."
  • "In one period, they will receive vitamin C (500 mg capsules taken twice daily); in the other, a placebo."
  • "Assessments will occur on Days 0, 7, and 14 of each intervention period and include: Anthropometric measurements; Resting blood pressure; Fasting blood samples; and 3-day food records."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

This study is testing whether taking vitamin C every day can help improve gut health and reduce inflammation in adults with obesity. Poor gut health-sometimes called "leaky gut"-can allow harmful substances from bacteria to enter the bloodstream, which may lead to inflammation and increase the risk of heart disease and liver problems. Participants will complete two study periods, each lasting two weeks, with a two-week break in between. In one period, they will take vitamin C; in the other, a placebo. During each period, researchers will collect blood, urine, and stool samples, ask participants to track their diet and activity, and perform a test to measure gut permeability. There are minimal risks, such as discomfort from blood draws or temporary stomach upset from a sugar drink. While participants may not directly benefit, their involvement will help researchers learn whether vitamin C is a safe and effective way to improve gut health in people with obesity.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Official eligibility criteria

Inclusion Criteria: * English speaking * Men and women between 18-50 years of age * BMI 30-40 kg/m² * Resting blood pressure \<140/90 mm Hg * No use of multivitamin/vitamin C supplement within past 1-month * Non-vegetarian/non-vegan * Willingness to follow a diet low in fruits and vegetables for two, 2-week periods Exclusion Criteria: * Current smoker or vaper, including tobacco, cannabis, or nicotine products * Alcohol consumption \>2 drinks/day * Use of antibiotics within past 1-month * Use of probiotic supplements within past 1-month * Use of anti-inflammatory drugs within past 1-month * Individuals with unmanaged or poorly controlled diabetes, dyslipidemia, hypertension * Known history of bleeding disorders, hemochromatosis, or kidney stones * For Women: Pregnancy, lactation, or change in birth control within the past 3-months * Use of certain medications that may interact with vitamin C, including blood thinners, some antiviral drugs (e.g., indinavir), and certain antipsychotic medications (e.g., fluphenazine).

Study sites (1)

OH